The two known estrogen receptors, ER␣ and ER␤, are hormone-inducible transcription factors that have distinct roles in regulating cell proliferation and differentiation. Previously, our laboratory demonstrated that ER␣ exhibits stereoselective ligand binding and transactivation for several structural derivatives and metabolites of the synthetic estrogen diethylstilbestrol. We have previously described the properties of indenestrol A (IA) enantiomers on ER␣. In the study presented here, the estrogenic properties of the S and R enantiomers of IA, IA-S and IA-R, respectively, were expanded to examine the activity in different cell and promoter contexts using ER␣ and ER␤. Using human cell lines stably expressing either ER␣ or ER␤, we found that IA-S was a more potent activator of transcription than IA-R through ER␣ in human endometrial Ishikawa and breast MDA-MB 231 (MDA) cells. Interestingly, IA-R was more potent on ER␤ when compared with ER␣ in MDA, but not in Ishikawa cells, and IA-R exhibited equally low binding affinities to ER␣ and ER␤ in vitro in contrast to its cell line-dependent preferential activation of ER␤. Alignment of the protein structures of the ligand-binding domains of ER␣ and ER␤ revealed one mismatched residue, Leu-384 in ER␣ and Met-283 in ER␤, which may be responsible for making contact with the methyl substituent at the chiral carbon of IA-S and IA-R. Mutagenesis and exchange of this one residue showed that the binding of IA-R and IA-S was not affected by this mutation in ER␣ and ER␤. However, in transactivation studies, IA-R showed higher potency in activating L384M-mutated ER␣ and wild-type ER␤ compared with wild-type ER␣ and M283L-mutated ER␤ in all cell and promoter contexts examined. Furthermore, IA-R-bound ER␣ L384M and wild-type ER␤ displayed enhanced interactions with the nuclear receptor interaction domains of the coactivators SRC-1 and GRIP1. These data demonstrate that a single residue in the ligand-binding domain determines the stereoselectivity of ER␣ and ER␤ for indenestrol ligands and that IA-R shows cell type selectivity through ER␤.
The estrogenic effects of a variety of structurally diverse endogenous and xenobiotic compounds are mediated through the estrogen receptors (ER␣ and ER␤), 1 which function as ligand-inducible transcription factors for genes involved in cell growth, proliferation, and differentiation (1) . Studies using knock-out mice for the two ER subtypes (␣ERKO and ␤ERKO, respectively) have revealed that each receptor plays a unique role in estrogen biology in a wide variety of target tissues (2) . Furthermore, in vitro studies indicated that ER␣ and ER␤ display marked differences in binding affinity and activation by natural and synthetic ER ligands (3, 4) . Interestingly, although ER␤ shows lower binding affinity for and activation by endogenous estrogens, several xenoestrogens preferentially bind and activate ER␤ (3). These observations have prompted further studies aimed at elucidating the molecular mechanisms of action of ER␣ and ER␤, and the search for ER subtype-selective agonists that could be used to evaluate the physiological roles of each receptor.
Diethylstilbestrol (DES) is a known carcinogen, which is oxidatively metabolized to a variety of metabolites with varying degrees of hormonal activity (34) . Indenestrol A (IA) is a metabolite derived from DES that has high binding affinity for ER␣ but weak biological activity (35) . IA exists as a racemic mixture of enantiomers, IA-S and IA-R (36) , which have a methyl substitution on the chiral carbon ( Fig. 1) . Previously, our laboratory demonstrated that IA-R displays a lower binding affinity and transactivation potency on ER␣ than IA-S (5), which may help explain the differential biological activity and allow the study of the stereoselectivity of ligand binding and transcriptional responses of ERs.
The discovery of ER␤ prompted us to investigate whether both ER subtypes would exhibit the same stereoselectivity for the IA enantiomers. Human ER␣ and ER␤ share high sequence homology (97%) in the central DNA-binding domain, but only moderate conservation (60%) in the C-terminal ligand-binding domain (LBD) and activation function-2 (AF-2). Since AF-2 mediates the ligand-dependent transcriptional activities of both ER subtypes (1) , it is possible that structural differences within this region could account for differences in the specificities of ER␣ and ER␤ for several estrogenic chemicals (4, 6) .
To expand our knowledge about the molecular determinants of the stereoselectivity of ER␣ and ER␤, we have characterized the ability of IA-S and IA-R to function as agonists/antagonists of the two ER subtypes. For the study of ER subtype-specific activation, stable cell lines were established by transfecting MDA-MB 231 (human breast adenocarcinoma; MDA) and Ishikawa (human uterine adenocarcinoma) cells with human or mouse ER␣ or ER␤. Using these cell models and in vitro binding assays, the ability of the IA enantiomers to bind ER␣ and ER␤, activate ERE-mediated transcription, and regulate coactivator recruitment was studied and compared between the two ER subtypes. Alignment of the LBDs of ER␣ and ER␤ revealed one mismatched amino acid (Leu-384 and Met-283, respectively) that may be responsible for making contact with the methyl substituent at the chiral carbon of IA-S and IA-R. This observation suggested that this residue could account for the functional differences observed between the two ER subtypes, a hypothesis that was further investigated in this study.
EXPERIMENTAL PROCEDURES
Materials and Biochemicals-Media, serum, supplements, enzymes, and chemicals were purchased from Sigma.
Cell Culture-Ishikawa and MDA-MB 231 (MDA) were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10 and 5% fetal bovine serum (FBS), respectively, and penicillin/streptomycin. For MDA, 5 g/ml insulin was added to the culture medium. Human hepatoma HepG2 were maintained in minimum essential medium (MEM) supplemented with 10% FBS, 1 mM sodium pyruvate, 2 mM glutamine, and 0.1 mM non-essential amino acids in flasks coated with 0.1% gelatin. Cells were cultured at 37°C in a 5% CO 2 -humidified atmosphere.
Expression Vectors and Reporter Constructs-For the generation of cell lines stably expressing mouse (m) or human (h) ER␣ or ER␤, the cDNAs of mER␣ (GenBank TM accession M38651), mER␤ (U81451, Ref. Stable Transfection of Human Cells with the cDNAs of h/mER␣/␤-MDA and Ishikawa cells were seeded in 6-well plates for stable transfection. Transfection of cells was performed with the FuGENE 6 reagent according to the manufacturer's protocol with 0.5 g of DNA and 1 g of FuGENE 6 (Roche Diagnostics Corp.) per well in DMEM/F12 supplemented with 1% FBS. Three days after transfection with the pcDNA3 vector containing either the mER␣, mER␤, hER␣, or hER␤ cDNA, cells were trypsinized and seeded in 60-mm tissue culture plates. Stable clones were selected by adding 200 -400 g/ml G418 to the culture medium. After 4 weeks of selection, 10 -20 clones each for mER␣, mER␤, hER␣, or hER␤ in MDA and Ishikawa were isolated and cultured separately in medium with 100 g/ml G418. Control cell lines were established by transfecting parental MDA and Ishikawa lines with the empty pcDNA3 vector.
RNase Protection Assay (RPA)-For the generation of riboprobe templates for hER␣, a fragment corresponding to base pairs (bp) 1785-2092 of the cDNA and for hER␤, a fragment corresponding to bp 1820 -2011 of the cDNA were subcloned into pDP18 (Ambion, Austin, TX), respectively. A human cyclophilin probe (Ambion) was used as an internal control. Antisense riboprobes were generated from the linearized templates using the Maxiscript kit (Ambion) and [ 32 P]CTP (Amersham Biosciences). RPAs were performed using the HybSpeed kit from Ambion according to the manufacturer's instructions (Ambion). 10 g of total RNA of each sample, isolated with the Trizol reagent according to the manufacturer's protocol (Invitrogen), was analyzed. 5 g of RNA isolated from untreated MCF-7 (human breast carcinoma) cells and BG-1 (ovarian carcinoma) cells were used as positive controls for hER␣ and hER␤, respectively. RPAs were performed exactly as described previously (8) .
Analysis of ER Protein Expression Using Western Blotting-Nuclear extracts were prepared as described previously with modifications (9, 10) . Aliquots containing 100 g of protein were analyzed on 10% Trisglycine polyacrylamide gels (NOVEX, San Diego, CA) and electroblotted onto nitrocellulose membranes (Hybond-ECL, Amersham Biosciences) as described previously (8) . The membrane was probed with either 1 g/ml H222 ER␣ antibody (kindly provided by G. Greene, University of Chicago, Chicago, IL) or 2 g/ml anti-ER␤ antibody (06-629, Upstate Biotechnology, Lake Placid, NY). Immunocomplexes were detected with a horseradish peroxidase-conjugated anti-rat (ER␣) or anti-rabbit (ER␤) IgG secondary antibody at 1:300 dilution (Oncogene, Cambridge, MA) and an ECL chemiluminescence kit (Amersham Biosciences).
Transient Transfection and Transactivation Assay-Cells were seeded on 24-well plates 15 h prior to transfection in phenol red-free DMEM/F12 supplemented with 5% dextran-coated charcoal stripped FBS (DCC/FBS). The reporter plasmids were transfected in DMEM/F12 supplemented with 1% DCC/FBS using FuGENE 6 according to the manufacturer's protocol. Each well received 0.5 g of reporter plasmid and 0.01 g pRL-CMV (Renilla luciferase for normalization; Promega, Madison, WI). A firefly luciferase reporter driven by three copies of the vitellogenin estrogen response element (3ϫERE-Luc) and a reporter containing the human complement 3 gene (C3) promoter (C3-Luc; kindly provided by D. McDonnell, Duke University, Durham, NC) were used to measure ER transcriptional activity (11) . For cotransfection of wild-type or mutated ER with the luciferase reporter vectors, 0.09 g of receptor plasmid, 0.4 g of reporter, and 0.01 g of Renilla luciferase normalization vector were used per well. After transfection, cells were incubated in medium supplemented with 5% DCC/FBS as described above with DES, 17␤-estradiol, IA-S, or IA-R (final concentration of vehicle ethanol 1%, v/v) for 20 h. Luciferase assays were performed using the Dual-Luciferase reporter assay system according to the manufacturer's protocols (Promega). Each value was normalized to the Renilla luciferase control, and each data point generated is the average of duplicate determinations. All experiments were repeated at least three times with consistent results.
Mammalian Two-hybrid Assays-For mammalian two-hybrid assays, HepG2 (human hepatoma) cells were plated in 24-well plates (coated with 0.1% gelatin) 24 h prior to transfection. DNA was introduced into cells using FuGENE 6. In standard transfections, 0.5 g of reporter 5ϫ-Gal4-TATA-Luc, containing 5 binding sites for the yeast Gal4 transcription factor, 0.09 g of receptor (either pVP16-hER␣, pVP16-hER␣L384M, pVP16-hER␤, or pVP16-hER␤M283L), 0.5 g of Gal4DBD-coactivator fusion (12, 13) (pM-SRC-1 (NR-box) or pM-GRIP1 (NR-box); plasmids kindly provided by D. McDonnell, Duke University, Durham, NC), and 0.01 g of the pRL-CMV Renilla luciferase normalization vector were used for each well. All transfections were performed in triplicate. Prior to transfection, cells were washed with phosphatebuffered saline, and 200 l of phenol red-free MEM containing 5% DCC/FBS was added to each well. Cells were incubated with the DNA/ FuGENE 6 mix for 6 h; receptor ligands in 200 l of phenol red-free MEM were then added to the cells and incubated for 20 h. Luciferase assays were performed using the Dual-Luciferase reporter assay system according to the manufacturer's protocols. Each value was normalized to the Renilla luciferase control, and each data point generated is the average of triplicate determinations. All experiments were repeated three times.
Ligand Binding Studies-Ligand binding was analyzed by competition of the test compound against 1 nM 17␤-[ 3 H]estradiol (71 Ci/mmol, PerkinElmer Life Sciences). Reactions were performed with 1 l of in vitro translated wild-type or mutated ER␣ and ER␤, respectively, in 100 l of TEGM buffer (10 mM TRIS, 1.5 mM EDTA, 3 mM EGTA, 3 mM MgCl 2 , 10% glycerol). ERs were in vitro translated with the TNT kit (Promega) using the pcDNA3 expression plasmids according to the manufacturer's protocol. Samples were incubated for 15 h at 4°C. Unbound 17␤-[ 3 H]estradiol was removed by adding DCC (0.25% charcoal, 0.025% dextran). Samples were spun at 3000 ϫ g, and remaining radioactivity contained in the supernatant was measured in a scintillation counter. Nonspecific binding was measured in the presence of 500ϫ excess of unlabeled estradiol. Scatchard analyses were performed with 0.1-2.5 nM 17␤-[ 3 H]estradiol. Site-directed Mutagenesis-The exchange of one amino acid in the LBD of hER␣ and hER␤ was accomplished using the QuikChange site-directed mutagenesis kit according to the manufacturer's protocol (Stratagene). The expression plasmids pcDNA3-hER␣ and pcDNA3-hER␤ were used to generate point mutations in the LBD. ER␣ L384 M was generated by exchanging the codon for leucine at position 384 for a methionine. The primers used for mutagenesis were: forward primer, 5Ј-CTAGAATGTGCCTGGATGGAGATCCTGATG (mutated codon in bold) and reverse primer, 5Ј-CATCAGGATCTCCATCCAGGCACAT-TCTAG-3Ј (mutated codon in bold). ER␤ M283L was generated by exchanging the codon for methionine at position 283 for a leucine. The primers used for mutagenesis were: forward primer, 5Ј-GGAGAGCT-GTTGGCTAGAGGTGTTAATGATG-3Ј (mutated codon in bold) and reverse primer, 5Ј-CATCATTAACACCTCTAGCCAACAGCTCTCC-3Ј (mutated codon in bold). The mutations in the plasmids used in the mammalian two-hybrid assay, pVP16-hER␣ L384M and pVP16-hER␤ M283L were created exactly as described above using the pVP16-hER␣ and pVP16-hER␤ plasmids (kindly provided by D. McDonnell, Duke University, Durham, NC) as templates for mutagenesis.
Statistical Analysis-Statistical analyses were performed using Student's t test (unpaired, one-tailed). Statistical significance is indicated by asterisk (p Յ 0.05).
RESULTS

Generation of Human Cell Lines with Stable Expression of ER␣ and ER␤-ER␣
and ER␤ were introduced into the ERnegative human mammary MDA and endometrial Ishikawa cell lines (14 -16) to obtain in vitro models to study the ligandmediated transcriptional responses of ER␣ and ER␤. For the generation of ER subtype and cell-specific models, each cell line was transfected with expression plasmids containing either the murine (m) or human (h) ER␣ or ER␤ cDNAs. Clonal cell lines with stable and comparable expression of the respective ER were established. The expression of ER␣ or ER␤ mRNA and protein in each cell line was confirmed by RNase protection assay (RPA) and Western blotting. The mRNA expression levels were between 1 and 4% of the expression of the housekeeping gene cyclophilin for mouse and human ER␣ or ER␤ expressed in MDA and Ishikawa cells (data not shown). The parental cell lines, as well as control cell lines stably transfected with the empty pcDNA3 vector, lacked endogenous ER␣ and ER␤ mRNA expression (data not shown). One cell clone for each cell line expressing functional mouse or human ER␣ or ER␤ was selected by assessing its estrogen responsiveness in transactivation assays using a reporter construct that contained three copies of the vitellogenin consensus estrogen response element (ERE, 3ϫERE-Luc) as reporter (data not shown). However, we were not able to establish a cell clone of the MDA line with expression of functional hER␣.
IA-R and IA-S Show Distinct Abilities to Activate ER␣ and ER␤ in Human Breast and Endometrial Cell
Lines-We first examined the ability of DES, E 2 , and the IA enantiomers IA-R and IA-S ( Fig. 1 ) to activate transcription through ER␣ and ER␤ in dose response experiments. Transactivation studies were performed in human MDA breast and Ishikawa endometrial cell lines using the 3ϫERE-Luc (containing 3 copies of the vitellogenin A2 ERE) and C3-Luc (containing the natural complement 3 (C3)) reporter constructs (11, 17) . The parental MDA and Ishikawa cell lines, as well as cells transfected with empty pcDNA3 vector, lacked any ligand-inducible transactivation of the 3ϫERE or C3 reporters, confirming the absence of endogenous functional ER␣ and ER␤ in these cell lines (data not shown). IA-S and IA-R, like E 2 and DES, were agonists of ER␣ and ER␤ in all cell and promoter contexts examined. In contrast to the weak agonism of IA-R on ER␣, this compound showed a high potency to activate both murine and hER␤ in MDA cells (Table I) . In Ishikawa cells, IA-R was less potent than IA-S in transactivation of ER␤ (EC 50 : 4.0 -8.0 nM for IA-R versus 0.2-0.5 nM for IA-S; see Table II ), but showed a slight, statistically significant preference for hER␤ over hER␣ on the 3ϫERE reporter (EC 50 : 4.0 Ϯ 3.6 nM for ER␤ versus 9.3 Ϯ 1.1 nM for ER␣; see Table II ). Interestingly, IA-R showed no marked difference in activation of ER␤ versus ER␣ in Ishikawa cells on the C3 promoter, whereas IA-R was a significantly more potent activator of transcription through ER␤ compared with ER␣ on both the 3ϫERE and C3 reporters in MDA cells, indicating a degree of cell type specificity influencing gene expression by the different ER subtypes (see Tables I and II) .
IA-R Has a Low Binding Affinity to ER␤ Although It Is a Potent ER␤ Agonist-
The finding that IA-R was a less potent activator of ER␣-mediated transcription compared with IA-S in MDA and Ishikawa cells (Tables I and II) confirmed data previously obtained in a yeast-based ER system (5). In addition, IA-R was a more potent activator of ER␤ in MDA and partly in Ishikawa cells compared with ER␣, which suggests that IA-R might also display a higher binding affinity for ER␤ as compared with ER␣. Competition binding studies with in vitro transcribed and translated hER␣ or hER␤ and 3 H-labeled E 2 confirmed our previous report (5) that IA-R has a low binding affinity for ER␣ (Table III) . Inconsistent with the transactivation data, however, IA-R also showed low binding affinity for ER␤, although both IA-S and IA-R exhibited slightly higher binding affinities for ER␤ than for ER␣ (Table III) .
Mutagenesis Studies Reveal That One Residue in the LBD Is Critical for the Stereoselective Ligand Activation of ER␣ and ER␤-
The differences in IA-R transactivation and binding of ER␤ as compared with ER␣ prompted us to examine differences in the LBD of the two ER subtypes that could contribute to the distinct pharmacology of IA-R on ER␣ and ER␤. The structures predicted by x-ray crystallographic studies of the LBDs of ER␣ and ER␤ provide a potential answer to this question (18, 19) . A structural model of the superimposition of the IA isomers with DES and genistein bound to the LBD of ER␣ and ER␤, respectively, predicts that several residues within the LBD of ER␣ and ER␤ could make contact with the methyl substituent at the chiral carbon of IA (Fig. 2) (18, 19) . From these selected residues, only leucine 384 (Leu-384) in ER␣ and the analogous methionine 336 (Met-336) in ER␤ are mismatched based on the alignment of the reported protein sequences of rodent and human ER␣ and ER␤ (18) (Fig. 2) . The ER␤ cDNA used in this study represents the short form of human ER␤ (GenBank TM accession no. AF051427) and position 283 is identical to position 336 of the full-length hER␤ cDNA used for the alignment in Fig. 2 . Furthermore, the complete sequence of the ligand-binding domain of the "short" hER␤ is identical to the full-length hER␤ cDNA (20, 21) . Notably, the residues Leu-384 and Met-283 are among those that may be involved in contact with the IA ligand when bound to the LBD.
To determine whether this one residue might be responsible for differences in the IA-R activation profile of ER␣ compared with ER␤, the mismatched residues in ER␣ and ER␤ were exchanged, i.e. Leu-384 in hER␣ was mutated to a methionine (ER␣ L384M) and Met-283 in hER␤ to a leucine (ER␤ M283L). We first determined whether the resulting ER mutants bound the IA enantiomers with different affinities than the wild-type ERs. Scatchard analysis of competition binding studies with in vitro transcribed and translated receptors revealed that wildtype and mutated ERs have comparable binding constants (Table IV) . Using competition binding studies we then determined the affinities of DES, E 2 , IA-S, and IA-R for wild-type and mutated ER␣ and ER␤ (Table V) . Relative binding affinities (RBA) compared with DES (set to 100) revealed no significant differences between the mutated and the wild-type ERs (Table V, ER␣ versus ER␣ L384M and ER␤ versus ER␤ M283L) for any ligand tested, indicating that the receptor binding affinity of the IA enantiomers was not affected by these mutations.
We then tested the ability of DES, E 2 , IA-S, and IA-R to activate wild-type and mutated ER␣ and ER␤. MDA and Ishikawa cells were transiently transfected with the cDNAs of wild-type or mutated hER␣ or hER␤. Transactivation assays were used as described above to measure receptor activity on the 3ϫERE and the C3 promoters (Tables VI and VII, Fig. 3 ). The cell line-dependent activation profile of IA-R observed in the stably ER expressing cell lines (Tables I and II) was confirmed by results obtained in cells transiently expressing ER (Tables VI and VII ). Fig. 3 shows the dose-response curves obtained on the C3 promoter in MDA cells. A compilation of all data obtained from transactivation assays performed in MDA and Ishikawa cells is given in Tables VI and VII, respectively. Specifically, these data confirmed that IA-R was a more potent activator of ER␤ than of ER␣ in MDA cells on both promoters examined (Table VI) . However, in Ishikawa cells IA-R was only slightly more potent in activating ER␤ compared with ER␣ on the 3ϫERE, but displayed no difference in potency between ER␣ and ER␤ on the C3 promoter (Table VII) . Consistent with their binding affinities, E 2 , DES, and IA-S showed no significant differences in their abilities to activate wild-type or mutated ER␣ and ER␤ in MDA and Ishikawa cells (Fig. 3 and Tables VI and VII). In contrast, the L384M mutation of ER␣ rendered IA-R more active compared with wild-type ER␣ (note the shift in the IA-R induced transcriptional potency of wildtype ER␣ compared with mutated ER␣ in Fig. 3B ). Consistent with this observation, the ER␤ mutant M283L exhibited lower c RBA values were calculated by setting IC 50 of DES to 100.
FIG. 2. Superimposition of IA-S (navy) and IA-R (green) molecules with genistein (red) bound to the LBD of hER␤.
Structural model of a part of the aligned LBD of hER␣ (blue) and hER␤ (red) drawn according to data presented in Refs. 18 and 19 using Molscript with the coordinates from the Brookhaven protein data bank (accession 2ERD and 2ERT). Superimposition of the ligands and numbering of residues was done based on the crystal structural data of genistein bound to the LBD of hER␤ (18) . potency than wild-type ER␤ when treated with IA-R (note the shift in the IA-R induced transcriptional activity of wild-type ER␤ compared with mutated ER␤ in Fig. 3D ). Furthermore, these effects were statistically significant in MDA cells on both promoters examined and in Ishikawa cells on the 3ϫERE reporter (Tables VI and VII) . Also, IA-R was a significantly less potent activator of the ER␤ mutant M283L than wild-type ER␤ on the C3 promoter in Ishikawa cells. However, although the L384M mutation of ER␣ rendered IA-R consistently more potent compared with wild-type ER␣ in Ishikawa cells in all performed experiments, this effect failed to reach statistical significance (EC 50 : 1.7 Ϯ 1.2 nM for ER␣ L384M versus 5.0 Ϯ 4.4 nM for ER␣, p ϭ 0.1; see Table VII ). The nature of these results suggests that these alterations were not apparently dependent on the gene regulatory sequence nor the cell type, but most likely a result of an intramolecular effect on the ER protein.
Mutagenesis of the Mismatched Residue in the hER␣ and hER␤ LBD Influences the Interaction of the IA-R-bound Receptors with Coactivators-
The observation that methionine 283 in hER␤ enhanced activation by IA-R suggested that this residue could be important in coactivator recruitment by the IA-R-liganded receptor. To test this hypothesis, mammalian twohybrid assays were performed to demonstrate the interaction of hER␣, hER␣ L384M, hER␤, and hER␤ M283L with the nuclear receptor-interacting regions (NR-boxes) of the coactivators SRC-1 and GRIP1. Previously, GAL4-DBD fusions of the SRC-1 and GRIP1 NR-boxes were shown to interact with ER␣ and ER␤ in an agonist-dependent manner, consistent with known receptor-coactivator interactions (25) . In the current study, as expected, the interactions between the Gal4DBD-SRC-1 and Gal4DBD-GRIP-1 NR-box fusions, and each receptor were enhanced by the addition of the agonists DES, E 2 , IA-S, and IA-R (Fig. 4, A-D) . The interaction of SRC-1 with wild-type and mutant hER␣ or wild-type and mutant hER␤ was similar for the DES, E 2 , and IA-S bound receptors (Fig. 4,  A and B) , in correlation with the transactivation data (Tables VI and VII, Fig. 3) . Notably, the interaction of SRC-1 in the presence of IA-R, which displayed a higher potency on hER␣ L384M and hER␤ compared with hER␣ and hER␤ M283L in transactivation studies (Tables VI and VII, Fig. 3 ), was enhanced when the methionine residue was present in hER␣ (hER␣ L384M) and in hER␤ (wild-type). GRIP1 binding to the IA-R-bound hER␣ L384M and hER␤ receptors was also clearly increased (Fig. 4, C and D) . None of the receptor or coactivator fusion proteins were capable of activating the 5ϫ-Gal4-TATALuc reporter vector when tested together with the empty Gal4-DBD or pVP16 vectors (data not shown). Taken together, the results from these studies indicate that methionine 283 in hER␤ plays an important role in IA-R activation through facilitating the recruitment of coactivators to the ligand-bound receptor, as illustrated for these types of ligand agonists.
DISCUSSION
Previously, our laboratory and others (5, (22) (23) (24) (25) determined that ER␣ exhibits stereoselective ligand activation and identified potential molecular determinants for ER␣ ligand-dependent activation and stereoselectivity. With the discovery of ER␤ (3, 4) the question emerged as to whether ER␤ also exhibits stereoselective ligand activation; this may explain the activity of the DES-type compounds as noted in the present studies and may elucidate the functional properties of ER␤. Complementary to this mechanistic question is the search for ER subtypespecific agonists or antagonists that would permit the identification of distinct activities and roles for ER␣ and ER␤ in estrogen target tissues. Katzenellenbogen and co-workers (26) were the first to determine the stereoselectivity of ER␤ using a chiral tetrahydrocrysene (THC). They found that the enantiomer R,R-THC activates ER␣ but is an antagonist on ER␤, from ER binding sites) were calculated from competition curves by logistic fit using the Origin Software (Microcal, Northampton, MA). The mean of IC 50 values determined from at least three independent experiments Ϯ S.D. is given.
c RBA values were calculated by setting IC 50 of DES to 100. whereas S,S-THC is an agonist on both ER␣ and ER␤ (26) .
TABLE VI Potency of ER ligands in MDA cells transiently transfected with wild-type and mutated ER␣ and ER␤
We showed in an earlier report that IA-S is a strong ER␣ agonist, whereas IA-R displayed only weak agonistic activity in a reconstituted ER transcription system in yeast (8) . In the study described here, we further explored the activity profile of these DES derivatives by determining the potency of the enantiomers of IA to activate ER␣ and ER␤ in different cell and promoter contexts. For analysis of cell type specificity, we generated human mammary and endometrial cell lines that stably express mouse or human ER␣ or ER␤. In transactivation studies using the cell lines generated, IA-S and IA-R exhibited agonistic and partial agonistic properties, respectively, through ER␣ and ER␤ for all cell and promoter contexts examined. This demonstrated that both IA enantiomers have agonistic properties similar to E 2 and DES, but with differing degrees.
However, although both IA enantiomers function as agonists of both ER subtypes, each ligand differed markedly with regard to its potency as an activator of ER␣ or ER␤. The IA enantiomer IA-R was a more potent activator of ER␤ compared with ER␣ in human mammary MDA cells. In endometrial Ishikawa cells, IA-R showed higher potency of activation on mER␤ than mER␣. However, both hER␣ and hER␤ showed a similar ability to activate transcription from the C3 reporter in the presence of IA-R, whereas IA-R was a more potent activator of hER␤ than hER␣ on the more sensitive 3ϫERE reporter. Taken together, these results indicated that IA-R could function as a potency and cell type-selective ER␤ agonist in MDA cells when compared with the endometrial Ishikawa cell line. Data reported here also indicated that ER␤ bound to IA-S is transcriptionally active to a similar degree in both mammary and endometrial cells. These findings support the notion that the activity of the ER can be dependent on the cellular context, as highlighted by the cell type-specific mixed agonist/antagonist activity of the selective ER modulator tamoxifen through ER␣ (27) .
The fact that IA-R is a weak agonist for ER␣ in all cell and promoter contexts examined suggests that either IA-R has a low binding affinity for ER␣ and/or the conformation of IA-Rliganded ER␣ does not favor activation. IA-R exhibited comparably low binding affinities for ER␣ and ER␤, which might be Fig. 3 and are given as mean Ϯ S.D. of at least three independent experiments. An asterisk indicates statistical significance of differences between EC 50 values of IA-R for mutated ER compared to wild-type ER (p Յ 0.05).
responsible for the weak activation of ER␣ by IA-R. However, the low binding affinity of IA-R for ER␤ is not predictive of its higher potency to activate ER␤ in MDA cells as compared with ER␣. Paige et al. (28) used affinity-selected peptides to show that ER␣ and ER␤ assume ligand-specific conformations, which are likely to modulate the activity of the liganded receptors. It is therefore reasonable to assume that a conformational change could cause the differential potencies of the activation of ER␣ versus ER␤ by IA-R, i.e. IA-R induces a conformational change permissive of ligand-dependent activation principally of ER␤, but only minimally of ER␣.
Recent studies analyzed the conformational changes that occur in ER␣ and ER␤ upon binding of the ER subtype-specific THC ligands (29, 30) . Kraichely et al. (29) showed that the THCs induced a distinct conformation of the receptors concomitant with quantitative differences in coactivator recruitment. They concluded that the ligand-dependent conformational change favors association of the receptor with coactivators and through that interaction causes transactivation by the ER. This mode of action is mechanistically described by the tripartite model of steroid hormone receptor action (31) . This model takes into account the ligand binding affinity, the conformation of liganded receptor, and the association of the receptor with coregulator molecules, i.e. coactivators. In line with this model, we hypothesized that IA-R permits transcriptional activation of ER␤ but not of ER␣, due to induction of a conformation resulting in altered coactivator recruitment.
We performed studies to test this hypothesis through experiments pinpointing the molecular determinants responsible for the differences in transactivation between ER␣ and ER␤ when bound by IA-R. Comparison of the amino acid sequence of the LBD of ER␣ and ER␤ revealed one mismatched residue within the LBD, Leu-384 in ER␣ and Met-283 in ER␤ that is likely to be proximal to the methyl substituent of the chiral carbon in IA based on the crystal structure data of liganded ER␣ and ER␤ (18, 19) . Given this information, we speculated that this residue could interfere with the bound IA, inducing a distinct conformational change either facilitating or impeding activation by ER. Indeed, when this residue was exchanged in ER␣ and ER␤, the potency of activation of mutated ER␣ L384M and   FIG. 4 . Mutagenesis of the one mismatched residue in the hER␣ and hER␤ LBD influences the interaction of the IA-R-bound receptors with coactivators. Mammalian two-hybrid assays were used to quantitate the interaction of hER␣, hER␣ L384M, hER␤, and hER␤ M283L with the coactivators SRC-1 and GRIP1. For these experiments, constructs containing the SRC-1 and GRIP receptor interaction domains fused to the Gal4 transcription factor DNA-binding domain (pM-SRC-1 (NR) and pM-GRIP1 (NR)) were used together with constructs containing either the hER␣, hER␣ L384M, hER␤, or hER␤ M283L cDNA fused in-frame to the VP16 activation domain. HepG2 cells were transiently transfected with the 5ϫ-Gal4-TATA-Luc reporter, the pRL-CMV normalization plasmid and either pM-SRC-1 (A and B) or pM-GRIP1 (C and D), together with pVP16-hER␣, pVP16-hER␣L384M, pVP16-hER␤, or pVP16-hER␤M283L. Following transfection, cells were treated with vehicle (veh) or 100 nM of E 2 , DES, or the indenestrol enantiomers IA-S or IA-R. After 20 h, cells were harvested and dual luciferase assays were performed. Each value was normalized to the internal luciferase control. Shown is a representative experiment with each data point being the average of triplicate determinations. Experiments were repeated three times with consistent results.
ER␤ M283L by IA-R changed accordingly: IA-R was a more potent activator of transcription of ER␣ L384M compared with wild-type ER␣ and also a less potent activator of mutated ER␤ M283L compared with wild-type ER␤. Importantly, this shift in activation of IA-R was independent of the cellular and promoter context tested and, furthermore, the activities of IA-S, as well as of DES and E 2 were not markedly affected by the Leu/Met mutational exchange. This suggests that IA-R has a unique ligand structure that is sensitive to this residue in the binding pocket and subsequently affects receptor conformation. As expected by the low binding affinity of IA-R observed for ER␣ and ER␤, this mutation did not affect the binding affinities of IA-R or IA-S to ER␣ and ER␤, supporting the concept of dissociation of ligand binding affinity from biological transcriptional activity. The residues Leu-384 in ER␣ and Met-283 in ER␤ are therefore likely to be important molecular determinants for the ER subtype-specific activity of IA-R.
Several studies have analyzed the molecular determinants of ligand-dependent activation of ER␣ (5, 22-25, 32, 33) . In most of these reports, mutations of residues in helices 11 and 12 of the AF-2 domain were described, and results indicated reduced DNA and/or ligand binding accompanied by weaker transactivation. Studies on the enantiomers of indenestrol showed that none of the ER␣ mutants analyzed reversed the stereoselectivity of ER␣ (5, 22) . In the latter study and in results presented here, the higher potency of IA-S to induce ER␣ activity was accompanied by a higher binding affinity of IA-S to ER␣ as compared with IA-R (36). Here, we showed that Leu-384 in helix 6 of hER␣ impedes the activation mediated by IA-R, independent of its binding affinity. Feng et al. (33) mutated the residues of lysine 362 in helix 3, valine 376 in helix 5, or glutamic acid 542 in helix 12 of the hER␣ LBD. All three mutations independently resulted in diminished transcriptional activity and coactivator binding (33) . Similar results were reported for mER␣; Mak et al. (25) mutated residues in the LBD and showed that the hydrophobic surface in the LBD, specifically Leu-376 in mER␣, which corresponds to leucine 379 in hER␣, is required for binding of the coactivator SRC-1 and subsequent transactivation. In this report, we examined and compared the putative molecular determinants of the ligand specificity of both ER␣ and ER␤. The leucine 384 residue of ER␣ impeded transactivation by IA-R, but not by other ligands, and therefore might also impede recruitment of coactivators only when IA-R is bound. In contrast, methionine 283 in the LBD of ER␤ enhanced transactivation induced by IA-R, which might be due to a conformational change leading to increased interactions with coactivators. Indeed, the interaction of SRC-1 and GRIP1 in the presence of IA-R, which was a more potent activator of hER␣ L384M and hER␤ compared with hER␣ and hER␤ M283L, was enhanced when the methionine residue was present in hER␣ (hER␣ L384M) and in wild-type hER␤. Taken together, this agrees with our suggested mechanism of IA-R activation: that IA-R, albeit with low binding affinity, induces a conformational change in ER␤ that facilitates ligand-dependent activation, whereas IA-R bound to ER␣ is unable to induce a favorable conformation and impedes activation.
In conclusion, this series of studies has revealed that IA-R is a potency-selective agonist for ER␤ in a cell type-specific manner, and a single residue in the LBD of ER␣ and ER␤ modulates their transcriptional activity in a cell type-independent fashion. Analysis of conformational changes and crystallographic and structural analysis of wild-type and mutated ER␣ and ER␤ bound to subtype specific agonists would further extend our understanding of the molecular mechanisms and structural determinants of ligand-specific transcriptional activity of ER␣ and ER␤.
